From the Division of Retrovirology, Walter Reed Army
Institute of Research and § Henry M. Jackson Foundation,
Rockville, Maryland 20850
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
CXCR4 is both a chemokine receptor and entry
co-receptor for T-cell line-adapted human immunodeficiency virus type
1. The genomic organization and promoter function for the entire
transcription unit of CXCR4 were determined. The gene
contains 2 exons of 103 and 1563 base pairs (bp) interrupted by a
2132-bp intron precisely between codons 5 and 6 of the coding
sequences. A transcription start site was identified 88 bp upstream of
the initiation codon, and a polyadenylate addition site was identified
22 bp 3' to a polyadenylation signal. Transient expression assays
defined a minimal promoter at positions 114 to +43 relative to the
transcription start site. This region contains a TATA box, a nuclear
respiratory factor-1 (NRF-1) site, and two GC boxes. Specific factor
binding to the NRF-1 site and GC boxes were demonstrated by gel
mobility shifts and DNase I footprinting. Site-directed mutagenesis
showed that the NRF-1 site is crucial for promoter activity providing the first evidence for the regulation of a signal transduction gene by
NRF-1. Sequences between
691 and
191 repress CXCR4 promoter activity. Further study of these regulatory elements will be important to understanding how CXCR4 functions as both a chemokine receptor and
human immunodeficiency virus type 1 entry co-receptor.
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Cellular entry of human immunodeficiency virus type 1 (HIV-1)1 requires binding to
both CD4 and to one of the seven transmembrane G-protein-coupled
chemokine receptors recently discovered to act as co-receptors (1-7).
Viruses that infect T-cell lines (T-tropic) form syncytia
(syncytium-inducing, SI), are frequently found in late-stage HIV
disease, and utilize the chemokine receptor CXCR4; macrophage-tropic
(M-tropic) viruses are non-syncytium-inducing (NSI), found throughout
disease, and utilize CCR5 (1-9). The CC chemokines RANTES, MIP-1,
and MIP-1
are natural ligands for CCR5 (10, 11), and the CXC
chemokine stromal cell-derived factor-1 (SDF-1) is the only known
natural ligand for CXCR4 (1, 7, 10, 11). Ligand binding to both
receptors is associated with G-protein-coupled signal transduction and
leukocyte chemoattraction (1, 7), as well as partial viral entry
antagonism (12). Viral entry and signal transduction are separable
functions for CCR5 (13-15), but the two may be biologically related to
viral pathogenesis.
CCR5 and CXCR4 are both expressed in peripheral blood T-lymphocytes and monocytes (3, 4, 10, 16), but in T-cells, CCR5 expression is largely confined to the activated, memory subset (16, 17) whereas CXCR4 expression is largely confined to the naive T-cell population (16). CXCR4 has also been reported to be expressed on peripheral blood B-cells (16). CXCR4 cell surface density on peripheral blood T-cells is rapidly up-regulated in response to phytohemagglutinin stimulation or interleukin-2 priming, whereas CCR5 shows up-regulation only in response to interleukin-2 (16, 17) similar to other CC chemokine receptors (18). Although both CCR5 and CXCR4 are expressed on monocytes, CXCR4 expression is very low in mature macrophages.2 CXCR4, but not CCR5, is expressed in typical CD4+ human neoplastic T-cell lines such as Sup-T1, H9, HUT 78, Jurkat, and A3.01, which explains the differential ability of such cells to support productive infection with T-tropic and not M-tropic virus (3, 4, 6). An exception is the PM-1 line, which produces both co-receptors and can be infected with some M-tropic as well as T-tropic HIV-1 strains (5, 20).
Evolution of co-receptor use from CCR5 to CXCR4 is coincident with progression to AIDS in approximately half of all HIV-1-seropositive subjects (21-23). The host and viral factors that govern this change in HIV-1 co-receptor use are poorly understood. We have determined the genomic organization of the CXCR4 transcription unit and characterized the basic cis- acting elements in its promoter to provide the conceptual framework to begin to address these questions.
![]() |
EXPERIMENTAL PROCEDURES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Cloning and Sequencing--
A total of 6 × 105
plaques from a human peripheral blood mononuclear cell (PBMC) genomic
library prepared in the bacteriophage vector Lambda-DASH II
(Stratagene, Inc., San Diego, CA) were screened with a
32P-random prime labeled cDNA probe (pcDNA-fusin)
representing the entire coding sequences of CXCR4 (cDNA
sequence position numbers 68-1134, according to GenBank accession
number X71635; see Ref. 24). Three highly plaque-purified clones were
then screened with a 5' 32P-end-labeled oligonucleotide
probe from the 5' end of the coding sequence (cDNA sequence
position numbers 17-49) resulting in a single, strongly hybridizing
clone, CXCR4-7a. Purified bacteriophage DNA from
CXCR4-7a was
digested with the restriction endonuclease NotI, the
14-kilobase insert was subcloned into the pBluescriptIIKS- vector
(Stratagene, Inc.) to generate pCXCR4-7a, and a 5160-bp portion of the
insert containing the CXCR4 transcription unit was completely sequenced
on both strands using an ABI model 373A DNA sequencer and
dye-terminator reactions (Applied Biosystems, Inc., Foster City, CA).
Contigs were compiled using Sequencher version 3.0 software (Gene Codes
Corp., Ann Arbor, MI). The final sequence, given in Fig. 1, was
deposited in GenBank (accession number AF005058). Sequence analysis was
performed using the Neural Network approach for prediction of splice
donor/acceptors (25) and promoters (26) using interactive
software.3 Transcription
factor binding site analysis was performed using the TESS and
MatInspector interactive software
packages.4
Genomic Southern Analysis-- High molecular weight DNA was extracted from the PBMCs of two HIV-1-seronegative human donors using the IsoQuick method (ORCA Research, Inc., Boswell, WA). Aliquots (10 µg) of these genomic DNAs and 1-µg amounts of purified, NotI-digested insert from pCXCR4-7a were separately digested to completion with restriction endonucleases BamHI and PvuII. The products were electrophoresed through a 0.8% agarose gel, transferred to a nylon membrane (Hybond-N, Amersham Corp.), probed with the 32P-random prime labeled pcDNA-fusin insert sequences, washed, and imaged using a model 850 PhosphorImager (Molecular Dynamics, Inc., Sunnyvale, CA).
5' RNA End-mapping-- Total cellular RNA was purified from the human neoplastic T-cell lines HUT 78 and PM-1 cells using the RNAzol B technique (Tel-Test, Inc., Friendswood, TX). RNA (50-µg amounts) was dissolved in 5 µl of water and hybridized with 100 fmol of the 5' 32P-end-labeled oligonucleotide probe PE1, 5'-CCCTCGGCGTCACTTTGCTACCTGCTGC (sequence positions 991-964 according to Fig. 1), dissolved in 1 µl of water at 58 °C for 20 min in 50 mM Tris-HCl, pH 8.3, 50 mM KCl, 10 mM MgCl2, 10 dithiothreitol, 1 mM each deoxyribonucleotide triphosphate (dNTP), and 0.5 mM spermidine. Parallel reactions were performed with [32P]PE1 in the absence of RNA. The reactions were then allowed to cool for 10 min at room temperature prior to incubation with 10 units of avian myeloblastosis virus reverse transcriptase (Promega, Inc., Madison, WI) in the presence of 50 mM Tris-HCl, pH 8.3, 50 mM KCl, 10 mM MgCl2, 10 mM dithiothreitol, 0.5 mM spermidine, 1.0 mM dNTP, and 2.8 mM sodium pyrophosphate at 42 °C for 30 min. The reactions were electrophoresed through a denaturing 7% polyacrylamide sequencing gel along with a sequence ladder generated with unlabeled PE1 and pCXCR4-7a template using [35S]dATP and Sequenase version 2.0 (U. S. Biochemical Corp.), dried down, and visualized by autoradiography.
3' RNA End-mapping-- A CXCR4-specific oligonucleotide 3'RACE1 5'-CCCAGCTGTTTATGCATAGA (sequence position 4537-4556) was used to perform 3'-rapid amplification of cDNA ends (3'-RACE) using 2 µg of RNase-free, DNase I-treated total cellular RNA from HUT 78 cells with a kit purchased from Boehringer Mannheim. Control reactions performed in the absence of RNA produced no amplified material. The specific 240-bp 3'-RACE product was identified by hybridization with primer 3'RACE2, 5'-CAGTTTTCAGGAGTGGGTTG (sequence position 4666-4685), agarose gel purified using the QIAEX II method (Qiagen, Inc., Chatsworth, CA), ligated into the vector pCR2.1 (Invitrogen, Carlsbad, CA), and the nucleotide sequence of multiple molecular clones was determined.
Promoter Mapping Experiments--
A nested series of 5'
deletions anchored to a common 3' sequence and a nested series of 3'
deletions anchored to a common 5' sequence were generated from
sequences representing the putative CXCR4 promoter elements
and directionally cloned 5' to the chloramphenicol acetyltransferase
(CAT) gene in the vector pKSCAT, a homologue of pSKCAT (27). The
inclusive sequence positions of each deletion clone are 5'1
(261-1037), 5'
3 (759-1037), 5'
5 (836-1037), 5'
7 (885-1037), 5'
9 (909-1037), 3'
1 (759-992), 3'
2 (759-929),
3'
3 (759-905). A modification of 5'
7, NRF-1
, was generated in
which the nucleotides GCG at sequence positions 896-898 were changed to TTT. All constructs were confirmed by DNA sequencing. Complete panels of these constructs were transfected in triplicate into A3.01,
HUT 78, and Sup-T1 cells by electroporation using a method described
previously (28) with the following modifications. For each
electroporation, 17 µg of CAT construction was electroporated into
1.5 × 107 cells with 3 µg of the
-galactosidase
reporter construction pCMV
-gal (28), 25 µg of lysate was used for
each CAT assay, and between 1 and 15% of the lysate was used to
determine
-galactosidase activity. Positive control transfections
were performed with the HIV-1 long terminal repeat reporter plasmid
pU3R-III (29) and negative control transfections were performed with
parental pKSCAT. Assays were performed within the linear range of the
assay (1-25%). Raw percent conversions were corrected for background
by subtraction of pKSCAT activity, normalized to
-galactosidase
activity to control for transfection efficiency, and expressed as a
relative percentage of the pU3R-III-positive control to normalize
between experiments.
DNase I Footprinting Assays--
A plasmid containing the
5'-flanking region of CXCR4 (5'3) was digested with the
restriction endonucleases KpnI and XmaIII to
obtain a fragment (sequence position numbers 758-933) with unique 3'-
and 5'-overhanging termini, respectively. This restriction fragment was
gel-purified and labeled using [
-32P]dCTP and the
Klenow fragment of DNA polymerase holoenzyme (New England Biolabs,
Inc.). Footprinting was performed using 16 µg of A3.01 nuclear
extracts prepared as described previously (30) and DNase I (Promega,
Inc.) per the protocol specified in the technical bulletin of the
manufacturer. The same unlabeled restriction fragment was used to
generate a Maxam-Gilbert G+A chemical sequencing ladder as described
previously (31). Bovine serum albumin (16 µg, New England Biolabs,
Inc.) was used in place of nuclear extracts in the control reactions.
The reaction products were deproteinized, electrophoresed through a 6%
denaturing polyacrylamide gel, dried down, and visualized by
autoradiography.
Electrophoretic Mobility Shift Assays-- For NRF-1 studies, a 26-bp portion of the CXCR4 promoter (sequence positions 885-910) containing the consensus NRF-1 site was synthesized as two complementary oligonucleotides. A mutant form of these oligonucleotides was also synthesized (Fig. 5A). For standard binding experiments, 0.5-ng amounts of these 32P-end-labeled probes were incubated with 8 µg of A3.01 nuclear extracts at 10 °C for 20 min in a reaction buffer containing 50 µg/ml poly(dI-dC) (Pharmacia Biotech Inc.), 10 mM Tris-HCl, pH 7.5, 50 mM NaCl, 1 mM EDTA, 1 mM dithiothreitol, 5% (v/v) glycerol in a total reaction volume of 20 µl. For supershift experiments, 1 µl of NRF-1 antiserum (kindly provided by Dr. R. Scarpulla, Northwestern University) was subsequently added and incubated at room temperature for an additional 30 min. As a nonspecific control, 1 µl of Sp4 antibody (Santa Cruz Biotechnologies, Inc.) was used for both NRF-1 and Sp1 EMSAs. For competition experiments, 100-fold molar excess (50 ng) of unlabeled wild-type or mutant oligonucleotide was added and allowed to incubate with the nuclear extract at room temperature for 20 min prior to the addition of labeled oligonucleotide. For GC box studies, a 46-bp portion of the CXCR4 promoter (sequence positions 842-887) containing GC boxes I and II (Fig. 1) was synthesized as two complementary oligonucleotides. An oligonucleotide with mutations in both of these GC boxes was also synthesized (Fig. 5B). The reaction conditions differed from the NRF-1 experiments in that the poly(dI-dC) concentration was increased to 250 µg/ml, 1 footprinting unit of purified Sp1 protein (Promega, Inc.) was used in place of nuclear extracts, 1 µg of bovine serum albumin was added to each binding reaction, and 1 µl of Sp1 antiserum (Santa Cruz Biotechnologies, Inc.) was used for supershifts. The DNA-Sp1 binding reactions were carried out at room temperature for 10 min. Binding complexes were resolved on native polyacrylamide gels and visualized by autoradiography essentially as described previously (32).
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Isolation and Structural Organization of the Human CXCR4
Gene--
Screening of a human PBMC genomic DNA library with a probe
consisting of the entire CXCR4 coding sequence yielded three
bacteriophage clones of which a single clone, CXCR4-7a, hybridized
with oligodeoxynucleotide probes representing the extreme ends of the
published coding sequences (24). As this raised the possibility that
the entire transcription unit was contained on the 14- kilobase pair
insert of this clone, it was chosen for nucleotide sequencing.
Comparison of the 5160-base pair genomic sequence obtained (Fig.
1) with the cDNA sequence suggested
that this was so. The 67-base pair 5'-untranslated region of the
cDNA sequence was contiguously identified in the genomic sequence
between positions 971 and 1037 with the initiating methionine codon
beginning at position 1038. Following 15 base pairs of coding sequence
corresponding to amino acid residues M-E-G-I-S, a consensus splice
donor was encountered followed by a 2132-base pair intron (sequence
position 1053-3184) precisely after the third base of codon 5 at
position 1052. A consensus splice acceptor was identified at the 3'
terminus of the intron followed by 1044 base pairs of coding sequences
(positions 3185-4228) whose open reading frame started with the first
base of codon 6 (isoleucine) and ended with a TAA codon. Taken
together, these two exons comprised all 352 amino acids predicted from
the cDNA sequence (24). The putative polyadenylation signal,
AATAAA, was identified 498 bp 3' to the TAA codon starting at position
4726 of the genomic sequence, and the remaining 21 bp of the
3'-untranslated region predicted from the cDNA sequence was
identified downstream contiguous with the published cDNA.
|
Identification of the CXCR4 Transcription Initiation and
Termination Sites--
To better define the 5' and 3' boundaries of
the transcription unit, RNA end-mapping studies were performed. Primer
extension studies were performed with a 32P-end-labeled
primer (PE1) from the 5'-untranslated region of CXCR4 using
either no RNA template (lane ()) or total cellular RNA
from HUT 78 cells (lane (+)) (Fig.
2). PE1 was also used to generate a
dideoxy sequencing ladder from clone 5'
3 (Fig. 2, lanes
GATC), which were co-electrophoresed with the primer extension reactions. The mock primer extension lane revealed multiple,
nonspecific extension products. However, a family of three specific
extension products was identified centered on the dominant, central C
residue (Fig. 2, arrow) of the nucleotide triad 5'-ACT
corresponding to the sense triad of 5'-AGT at positions 949-951. Thus,
the G at position 950 was designated the transcription start site/5'
transcription unit border and assigned the identifier +1. Similar 5'
ends were identified using total cellular RNA from A3.01 and PM-1 cells (data not shown). The CXCR4 transcription start site is 21 bp upstream of the 5' cDNA terminus identified previously (24) and
32 bp downstream of a canonical TATA box, TATAA, at sequence positions
919-923 (Fig. 1). The 3' end of the CXCR4 transcription unit was mapped using 3'-RACE to sequence position 4747 (data not
shown) 22 bp downstream of a canonical polyadenylation addition signal,
AATAAA, at positions 4726-4731 in agreement with the published 3'
cDNA terminus (24).
|
Positional Mapping of the CXCR4 Promoter-- The CXCR4 5'-flanking region sequences were searched for known promoter elements. The sequences immediately upstream of exon 1 and the +1 site were identified as promoter and transcription start sites, respectively, by the Neural Net Promoter prediction algorithm (26). Sequences 5' to the transcription start site included a TATA box, a potential NRF-1 site, and four potential antisense GC boxes, of which the most distal pair, GC box III and IV, overlap (Fig. 1).
A nested series of 5' deletions were generated starting from position
|
Identification of Potential cis-Acting Elements by Footprint
Analysis--
A restriction fragment obtained by digesting a plasmid
containing sequence positions 758-933 with KpnI and
XmaIII was used for DNase I footprinting analysis with A3.01
cell nuclear extracts (Fig. 4). Compared
with the control lane using bovine serum albumin (lane 2),
there was a general decrease in band intensity from positions 88 to
49 relative to the transcription start site to include the two
proximal GC boxes and the NRF-1 site which was heavily protected
(lane 1). Taken together with the reporter gene analyses,
the importance of these promoter elements was further substantiated.
|
Transcription Factors NRF-1 and Sp1 Bind to the CXCR4 Promoter-- To determine if specific transcription factors corresponding to the NRF-1 site and GC boxes bound to their respective binding sequences in the CXCR4 promoter, electrophoretic mobility shift (EMSA) experiments were performed. Oligonucleotides representing CXCR4 promoter sequences containing either the wild type or mutant NRF-1 binding sites were used as EMSA probes with A3.01 cell nuclear extracts (Fig. 5A). No complex formation was seen in the absence of extract for both wild-type and mutant probes (Fig. 5A, lanes 1 and 7, respectively). Wild-type probe generated one specific (C1) and two nonspecific (NS) complexes with A3.01 extract (lane 2), which was readily competed by unlabeled wild-type probe (lanes 3) but not an excess of mutant probe (lane 4). Addition of NRF-1 antiserum (lane 5) but not nonspecific Sp4 antibody (lane 6) resulted in the supershift of C1 to C2. Only nonspecific complexes were observed with the mutant probe (lane 8). These data strongly suggest that NRF-1 specifically binds to the NRF-1 binding site in the CXCR4 promoter.
|
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
We have characterized the entire transcription unit of the human CXCR4 gene. The sequence of the gene has a very high GC content; the coding sequences are 50.3% GC, and the intron and 0.95 kilobase pairs 5' to the transcription start site are 56.9 and 53.1% GC, respectively, which is higher than 99% of human genes (36). The biologic significance of this observation is uncertain. However, the practical implication of this finding is that large portions of the gene are quite difficult to amplify by the polymerase chain reaction, which will make attempts to perform high through-put studies to look for genotypic polymorphisms in cohorts of subjects more difficult.
Polymorphisms that result in mutant chemokine receptor proteins have been identified for CCR5 (37, 38) and CCR2B (39). CCR5 polymorphisms correlate with delayed progression to AIDS (21, 40) and decreased susceptibility to HIV-1 infection (21, 38, 40), whereas the implications for CCR2B polymorphisms are less clear (19, 39). The finding of substantial polymorphisms in the coding sequence for CXCR4 may be less likely than for the other chemokine receptors. CXCR4 mRNA is widely expressed in a variety of hematopoietic and non-hematopoietic tissues, including brain, heart, kidney, lung, and liver (41, 42), which is a markedly larger distribution than the other identified chemokine receptors. There is so far only one identified ligand, SDF-1, which produces a lethal mutation when knocked out in mice (43), and both CXCR4 and SDF-1 genes show high interspecies conservation (9, 41). All of these findings argue for the criticality of a functional CXCR4 gene product, and against the likelihood of finding significant polymorphisms in human cohorts.
The validity of our proposed genomic organization is supported by multiple lines of evidence. Primer extension analysis was performed in multiple cell lines and yielded a strong single nucleotide band with weaker bands for the adjacent nucleotides on either side, but no other significant start sites. This start site was predicted before the performance of these experiments by the Neural Network algorithm (26) and is further supported by the presence of nearby upstream elements including TATA and GC box elements. The intron-exon boundaries contain consensus splice donor and acceptor sequences, were predicted by Neural Network (25) and maintain the open reading frame as predicted by the cDNA sequences (24). The polyadenylate addition site was quite precise when sequenced in multiple clones, occurs immediately downstream of a consensus polyadenylation signal, and agrees with previously published work (24). The size of mRNA species predicted by sum of the two exons and a 100-200-base pair poly(A) tail agrees with that observed by Northern analysis (6, 24).
Analysis of the CXCR4 5'-flanking sequence showed the
presence of several potential binding sites for known transcription factors. The importance of the two most proximal Sp1 sites, and to a
much greater degree, the NRF-1 site in the basal promotion of the
CXCR4 gene was shown by multiple, complementary experiments, including DNase I footprinting, transient transfection with
promoter/CAT constructs, site-directed mutagenesis of the NRF-1 site,
and mobility shift assays. The transient transfection experiments,
deleting from both 5' and 3' ends of the 5'-flanking region, localized the critical basal promoter sequences between positions 114 to +43
relative to the transcription start site (sequence positions 836 and
992). Deletion or mutation of the sequences containing the NRF-1 site
at positions
61 to
49 (sequence positions 889-901) essentially
abolished CXCR4 promoter activity.
NRF-1 is a nuclear encoded gene product that has been shown to be
important for the transcriptional regulation of multiple mitochondrial
genes involved in organelle biogenesis and cellular respiration (33).
Potential NRF-1 binding sites have also been identified in several
genes important for cell maintenance, growth, and proliferation such as
the genes for ornithine decarboxylase, 5-aminolevulinate synthase,
bcl-2, and DNA polymerase-, and signal transduction genes such as
those for cyclophilin, calmodulin, and murine GM-CSF (33). However, the
functional significance of these observations is unclear. Following
submission of this manuscript, Moriuchi and colleagues (45) described
the recovery of the proximal portion of the CXCR4 promoter
reported here and also demonstrated the importance of NRF-1 for
CXCR4 transcriptional regulation. These two reports
represent the first demonstration of the role of NRF-1 in the
expression of a signal transduction gene. Given the evidence for the
importance of CXCR4 in cellular development and its presence
on immune effector cells, it is easy to postulate that NRF-1 serves to
coordinate an increase in a cell's metabolic capacity in response to
inflammatory or proliferative signals, preparing the cell to migrate or
divide. This increased level of cellular activation has been previously
shown to be important for high level HIV-1 replication in target cells
(46).
Transient transfections done in several cell lines consistently showed
a degradation of promoter activity when sequences between 668 and
191 were present in the construct, suggesting the presence of
negative regulatory elements in this portion of the sequence. Precise
mapping of this region to delineate these elements is now in progress.
An inducible repressor element could conceivably be a target for the
development of therapeutic agents; if CXCR4 transcription could be blocked, entry of SI strains of HIV-1 into cells
might be inhibited.
Identification of two new co-receptors that also mediate HIV-1 and SIV entry, such as Bonzo (47, 48) and BOB (47), as well as reports of others (49), underscores the growing complexity of HIV-1 viral entry into target cells. Elucidation of the regulatory mechanisms that govern the interplay of these co-receptors will be important to a fuller understanding of HIV disease.
![]() |
ACKNOWLEDGEMENTS |
---|
We thank C. Bailey and C. Wang for technical assistance, C. Drew and D. Joynes for graphics, R. Scarpulla for NRF-1 antiserum, and M. Robb and D. Birx for support and helpful discussions. We are indebted to H. Moriuchi and A. Fauci for sharing unpublished data and insights.
![]() |
FOOTNOTES |
---|
* This work was supported in part by Cooperative Agreement DAMD17-93-V-3004 between the United States Army Medical Research and Materiel Command and the Henry M. Jackson Foundation for the Advancement of Military Medicine.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) AF005058.
¶ To whom correspondence and reprint requests should be addressed: Div. of Retrovirology, Walter Reed Army Institute of Research, 1600 E. Gude Dr., Rockville, MD 20850. Tel.: 301-762-0089; Fax: 301-762-7460; E-mail: nmichael{at}pasteur.hjf.org.
1 The abbreviations used are: HIV-1, human immunodeficiency virus type 1; bp, base pair(s); RACE, rapid amplification of cDNA ends; CAT, chloramphenicol acetyltransferase; PBMC, peripheral blood mononuclear cell; EMSA, electrophoretic mobility shift assay; M- and T-tropic, macrophage- and T-cell-tropic, respectively; contig, group of overlapping clones; SI, syncytium-inducing; NSI, non-syncytium-inducing; NRF-1, nuclear respiratory factor-1.
2 R. G. Collman, personal communication.
3 Software package can be obtained via the World Wide Web (http://www-hgc.lbl.gov/projects).
4 The TESS and MatInspector interactive software packages can be obtained via the World Wide Web (http://dot.imgen.bcm.tmc.edu:9331/seq-search/gene-search.html).
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|